SCM
CERE

Soleus Capital Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Soleus Capital Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-46,000
Closed -$1.46M – 121
2023
Q2 		$1.46M Sell
46,000
-109,000
-70% -$3.35M 0.16% 79
2023
Q1 		$3.78M Buy
+155,000
New +$4.55M 0.39% 55

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Soleus Capital Management's CERE Position: Q3 2023 in Review

Soleus Capital Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2023, closing a stake of 46,000 shares — an estimated $1.46M sold.

Soleus Capital Management first reported a position in CERE in Q1 2023 and held it in 2 quarters. The position peaked at $3.78M in Q1 2023. 119 funds tracked by Wall St. Rank hold CERE as of Q3 2023.

  • Soleus Capital Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Soleus Capital Management sold 46,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2023, an estimated $1.46M.
  • Soleus Capital Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Soleus Capital Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $3.78M in Q1 2023.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2023.

Based on Soleus Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.